Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.

Nature medicine - 1 Jun 2024

Rodón Jordi, Damian Silvia, Furqan Muhammad, García-Donas Jesús, Imai Hiroo, Italiano Antoine, Spanggaard Iben, Ueno Makoto, Yokota Tomoya, Veronese Maria Luisa, Oliveira Natalia, Li Xin, Gilmartin Aidan, Schaffer Michael, Goyal Lipika

Abstract excerpt

Fibroblast growth factor receptor (FGFR) alterations drive oncogenesis in multiple tumor types. Here we studied pemigatinib, a selective, potent, oral FGFR1-FGFR3 inhibitor, in the phase 2 FIGHT-207 basket study of FGFR-altered advanced solid tumors. Primary end points were objective response rate (ORR) in cohorts A (fusions/rearrangements, n = 49) and B (activating non-kinase domain mutations, n = 32). Secondary...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Morpholines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Progression-Free Survival

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Share to Pyrroles

Share to Receptor, Fibroblast Growth Factor, Type 1

Share to Receptor, Fibroblast Growth Factor, Type 3

Source

Open in PubMed Open full text

Identifiers

PMID: 38710951
DOI: 10.1038/s41591-024-02934-7
PMCID: PMC11186762

Genes

FGFR1
FGFR3
BAP1
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.PMID 38710951Read ↗

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements.Semantic proximity Read ↗

Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 RearrangementSemantic proximity Read ↗

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.Semantic proximity Read ↗

A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial.Semantic proximity Read ↗

A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors.Semantic proximity Read ↗

Outcomes of patients treated by FGFR inhibitors according to alteration types: An agnostic monocentric retrospective cohort.Semantic proximity Read ↗

Saturation mutagenesis identifies activating and resistance-inducing FGFR kinase domain mutations.Semantic proximity Read ↗

Prognostic Impact of Concomitant Genomic Alterations in FGFR2-Positive Cholangiocarcinoma Treated With Pemigatinib.Semantic proximity Read ↗

A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study.Semantic proximity Read ↗

A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma.Semantic proximity Read ↗

Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.Semantic proximity Read ↗

Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.